{"entity":{"id":"nct05299424","kind":"trial","name":"A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma","aka":[],"tldr":"A phase 1/2 trial of CM336_group 1 in multiple myeloma, run by Keymed Biosciences Co.Ltd, now recruiting.","summary":"A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT05299424 by Keymed Biosciences Co.Ltd, with 48 participants planned, started 2022-08-09 and due to reach its primary completion in 2026-12. Interventions recorded: CM336_group 1, CM336_group 2a, CM336_group 2b, CM336_group 3a, CM336_group 3b and CM336_group 4a.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05299424","url":"https://clinicaltrials.gov/study/NCT05299424"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["keymed"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05299424","phase":"1/2","setting":"A Multi-center, Open-label, Phase 1/2 Clinical Study of CM336 Injection in Patients With Relapsed or Refractory Multiple Myeloma","sponsor":"Keymed Biosciences Co.Ltd","enrolled":48,"outcomes":[]},"route":"/trials/nct05299424/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"company":[{"id":"keymed","kind":"company","name":"Keymed Biosciences (KYM Biosciences)","route":"/companies/keymed/"}]}}